Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
Pharmacotherapy is an effective treatment modality across psychiatric disorders. Nevertheless, many patients discontinue their medication at some point. Evidence-based guidance for patients, clinicians, and policymakers on rational discontinuation strategies is vital to enable the best, personalized treatment for any given patient. Nonetheless, there is a scarcity of guidelines on discontinuation strategies. In this perspective, we therefore summarize and critically appraise the evidence on discontinuation of six major psychotropic medication classes: antidepressants, antipsychotics, benzodiazepines, mood stabilizers, opioids, and stimulants. For each medication class, a wide range of topics pertaining to each of the following questions are discussed: (1) Who can discontinue (e.g., what are risk factors for relapse?); (2) When to discontinue (e.g., after 1 year or several years of antidepressant use?); and (3) How to discontinue (e.g., what’s the efficacy of dose reduction compared to full cessation and interventions to mitigate relapse risk?). We thus highlight how comparing the evidence across medication classes can identify knowledge gaps, which may pave the way for more integrated research on discontinuation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although our findings do cast a degree of doubt on the need for routine use of longer-term tapering regimens apart from any theoretical concerns.”
From Incidence and Nature of Antidepressant Discontinuation Symptoms (2025) · cites this paper as [3]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852 · cited 2×
“…for relapse following discontinuation: In bipolar disorder, young age of onset, psychotic features, numerous previous episodes, rapid cycling, comorbid anxiety, comorbid substance use, and persistent subthreshold symptoms are risk factors for recurrence, even during maintenance treatment [76].”
BackgroundSelf-citationPliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.022 · Cited by 1,545 · cited 1×
“In clinical practice, tapering stimulants is sometimes considered, while lacking evidence [139, 147].”
BackgroundSelf-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
The Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 2×
“25 % a f t e r 1 y e a r [ 3 ] 3 7 – 70 % [ 47 ] F i r s t e p i s o d e o f p s y c h o s i s ( FE P ) : c o n t i n u e a t l e a s t 1 – 2 y e a r s ( w i t h r a p i d f u ll r e m i ss i o n a n d f e w r i s k f a c t o r s , d i s c o n t i n u a t i o n a f t e r 6 m o n t h s m a y b e c o…”
BackgroundInfluentialCleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Research works printed but not linked: 3
- Tripp CC, Rak E, Burker E. A review of effective treatments for patients with co-occurring chronic pain and opioid addiction. VISTAS Online. 2017.
- Howland RH. Potential adverse effects of discontinuing psychotropic drugs. J Psychosoc Nurs Ment health Serv. 2010;48:11–4.
- National Guideline Centre (UK). Withdrawal from pharmacological treatment and drug holidays: attention deficit hyperactivity disorder: diagnosis and management: evidence review I. London: National Institute for Health and Care Excellence (NICE); 2018.
Cited by
Incidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Self-citationFung, C. H., Alessi, C., Martin, J. L., Josephson, K. R., Kierlin, L., Dzierzewski, J. M., Moore, A. A., Badr, M. S., Zeidler, M. R., Kelly, M. R., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.5020 · Cited by 28
Costa, B., & Vale, N. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154398 · Cited by 22
Photodegradation of typical psychotropic drugs in the aquatic environment: a critical review
Wang, C., Guo, R., Guo, C., Yin, H., & Xu, J. F. (2025) · Environmental Science Processes & Impacts · doi:10.1039/d4em00669k · Cited by 13
Montégut, L., Rousseau, A., Ungolo, C., Derosa, L., Fidelle, M., Alves Costa Silva, C., Routy, B., Zitvogel, L., Besse, B., Pasolli, E., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2528955 · Cited by 8
“44,45 Beyond the epidemiological association between benzodiazepine use and reduced efficacy of immunotherapy, the present study reveals a correlation between benzodiazepine consumption and stigmata of intestinal dysbiosis.”
Metadata
- Authors
- Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., Tiihonen, J., Veldman, S. E., Veling, W., Vis, R., de Wit, L. E., & Luykx, J. J.
- Affiliations
- Amsterdam Neuroscience (NL)
- Radboud University Nijmegen (NL)
- King's College London (GB)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- University of Helsinki (FI)
- University Medical Center Groningen (NL)
- St. Antonius Ziekenhuis (NL)
- Maastricht University Medical Centre (NL)
- Corresponding author
- Vinkers, Christiaan H.
- ORCID
- Venue
- Molecular Psychiatry
- Published
- 2024-03-19
- Volume
- 29
- Issue
- 8
- Pages
- 2575-2586
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- PMC
- PMC11412909
- OpenAlex
- W4392956861
- Cited by
- 51
- References
- 154
- Citations by year
- 2026: 32 · 2025: 13 · 2024: 5
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Työväentutkimus Vuosikirja (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Biogen
- Sunovion
- Wellcome Trust
- ZonMw
- Dainippon Sumitomo Pharma
- Gedeon Richter
- Shionogi
- Hersenstichting
- H. Lundbeck A/S
- Idorsia Pharmaceuticals
- HLS Therapeutics
- Cilag
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- antidepressants, antipsychotic drugs, benzodiazepines, mood stabilizers, opioids, stimulants, relapse risk, dose reduction, tapering, treatment duration, psychopharmacological treatment
- MeSH terms
- Antidepressive Agents, Mental Disorders, Benzodiazepines, Humans, Psychotropic Drugs, Recurrence, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuation of psychotropic medication: a synthesis of evidence across medication classes. https://app.cochat.ai/papers/10.1038/s41380-024-02445-4
- The paper
- Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., Tiihonen, J., Veldman, S. E., Veling, W., Vis, R., de Wit, L. E., & Luykx, J. J. (2024). Discontinuation of psychotropic medication: a synthesis of evidence across medication classes. Molecular Psychiatry. https://doi.org/10.1038/s41380-024-02445-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.